Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection-Reference-Cited by-同舟云学术

Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection

Published:2013-07-21 Issue:8 Volume:208 Page:1231-1239
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Janes Holly,Friedrich David P.,Krambrink Amy,Smith Rebecca J.,Kallas Esper G.,Horton Helen,Casimiro Danilo R.,Carrington Mary,Geraghty Daniel E.,Gilbert Peter B.,McElrath M. Juliana,Frahm Nicole

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/208/8/1231/16866123/jit322.pdf

Reference49 articles.

1. Immune-correlates analysis of an HIV-1 vaccine efficacy trial;Haynes;N Eng J Med,2012

2. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women;Baeten;N Eng J Med,2012

3. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial;Bailey;Lancet,2007

4. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women;Abdool Karim;Science,2010

5. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men;Grant;N Eng J Med,2010

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles;Journal of Virology;2024-08-20

2. Arenavirus-Based Vectors Generate Robust SIV Immunity in Non-Human Primates;Vaccines;2024-07-02

3. Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial;eBioMedicine;2024-02

4. Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys;npj Vaccines;2023-11-10

5. Mosaic HIV-1 vaccination induces anti-viral CD8 ⁺ T cell functionality in the phase 1/2a clinical trial APPROACH;Journal of Virology;2023-10-31